COVID-19
Conditions
Interventions
The control group:placebo+paxlovid
The experimental groupgroup:"Zengneng Jiedu Recipe"+paxlovid
Sponsors
Shanghai Tenth People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.18= age =80 years old, no gender limitation; 2.Meet the diagnostic criteria for mild and common cases in COVID-19 Diagnosis and Treatment Protocol (Trial Version 9) released by the National Health Commission ; 3.Voluntarily participate in the case registration study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe and critically ill COVID-19 patients; 2. Any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute trachea-bronchitis, sinusitis, otitis media and other respiratory diseases with impact assessment; 3. Patients with serious pulmonary interstitial disease, bronchiectasis, primary immune deficiency disease, congenital respiratory malformation, congenital heart disease, abnormal lung development and other basic diseases; 4. Patients with severe liver disease [ASpartate aminotransferase (AST), alanine aminotransferase (ALT) exceeding 5 times the normal upper limit], or with severe renal insufficiency or undergoing continuous renal replacement therapy, hemodialysis, or peritoneal dialysis; 5. Malignant tumors with multiple metastases that cannot be resected, hematologic diseases, malignant fluid, active bleeding, severe malnutrition, HIV, or severe neurological or psychiatric diseases; 6. Unwilling to cooperate with TCM syndrome differentiation to treat patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nucleic acid turning negative time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptom relief rate;ransfer rate of severe;Hospitalization days;7 days nucleic acid detection Ct value up to standard rate;Cytokines and lymphocyte subsets; | — |
Countries
China
Contacts
Public ContactLihong Fan
Outcome results
None listed